Medtronic posts highest annual revenue growth in a decade

Medtronic has delivered its highest annual revenue growth in 10 years, according to the fourth-quarter and full-year fiscal 2026 results the company released on Tuesday.

The medical device maker framed the fiscal year as a breakout period on the top line, with the annual growth rate reaching a level the company has not recorded since fiscal 2016. Management pointed to the print as evidence that its portfolio reshaping and investment priorities are translating into sustained demand across its businesses.

What does the result signal for Medtronic's trajectory?

The headline matters for finance teams watching the medtech sector. A ten-year high in annual revenue growth marks a clear departure from the mid-single-digit expansion that has characterized much of the company's recent history.

It also lands at a moment when investors have pressed large-cap device makers to demonstrate organic momentum rather than growth through acquisition. Medtronic's fiscal 2026 performance gives the company a stronger baseline heading into fiscal 2027 planning.

The fourth-quarter figures complete a year in which the company reported accelerated momentum. Details on segment performance, margin trajectory and guidance were published alongside the release.

Why does a decade-high growth rate matter?

Ten years is a long measurement window for a company of Medtronic's scale. The prior peak dated back to a period before several of the company's most significant portfolio changes.

Reaching a new high suggests the current growth engine — rather than a single quarter's timing or one-off items — has sustained output across four quarters. That durability is the metric CFOs and analysts typically discount for, and it is the one Medtronic is now able to claim.

For treasury and planning teams at peers, the result sets a benchmark: the largest players in medtech are growing again at rates that support reinvestment, pricing discipline and capital returns simultaneously.

What comes next?

Medtronic will now face the comparison-base question that follows every strong year. Fiscal 2027 guidance, issued with the results, will show whether management expects the momentum to hold against tougher prior-year comps.

The company's report also arrives amid broader sector pressure on procedure volumes, pricing and supply costs. Sustaining a decade-high growth rate into a new fiscal year would confirm the shift as structural rather than cyclical.

For now, the fiscal 2026 record stands as the company's strongest top-line performance since 2016 — a milestone Medtronic explicitly highlighted in announcing the results.